Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

Offering a simpler alternative to PET scans and CSF analysis, blood-based biomarker tests could improve accessibility of ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia Limited (Lilly) have signed a ...

Healthy obesity is defined as having a BMI of 25 kg/m² or higher without metabolic diseases or with only one metabolic ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

In a promising development for Alzheimer’s disease diagnostics, Veravas, Inc. and Phanes Biotech have announced their ...

Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

An 80-something patient came in for an annual visit recently and was worried that recent memory lapses might be symptoms of ...

We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.